Literature DB >> 9860004

Human leukocyte antigens associated with hyperthyroid Graves ophthalmology in Japanese patients.

K Ohtsuka1, Y Nakamura.   

Abstract

PURPOSE: To evaluate the association of human leukocyte antigen (HLA) types in Japanese patients with Graves ophthalmopathy.
METHODS: Japanese patients with severe ophthalmopathy (48 patients) and patients without ophthalmopathy (46 patients) were selected prospectively from 234 consecutive patients with hyperthyroid Graves disease. The criteria for severe ophthalmopathy were proptosis of 19 mm or more, or a 3-mm difference in exophthalmometry measurement between the two eyes, or diplopia at the primary eye position. The criteria for the absence of ophthalmopathy were proptosis of 16 mm or less, no diplopia, no lid retraction, and no thickening of extraocular muscles. Serologic HLA typing of class I and II antigens was performed in the two patient groups. The frequency of each HLA antigen in the two patient groups was compared to that in 767 unrelated normal healthy Japanese controls.
RESULTS: The frequencies of HLA-DR14 and DQ1 were significantly higher in the patient group with severe ophthalmopathy (35% and 75%, respectively) than in healthy controls (4% and 43%, respectively; corrected P < .05), and also greater than in the patient group without ophthalmopathy (13% and 55%, respectively; P < .01). On the other hand, the frequencies of HLA-B35, B54, DR4, and DQ4 were significantly higher in the patient group without ophthalmopathy (23%, 23%, 43%, and 30%, respectively) than in the patient group with severe ophthalmopathy (13%, 15%, 25%, and 19%, respectively; P < .01).
CONCLUSIONS: HLA-DR14 and DQ1 antigens may be genetic markers of predisposition to the development of severe ophthalmopathy. In addition, HLA-B35, B54, DR4, and DQ4 may be genetic markers of resistance to severe ophthalmopathy. Variation in the severity of ophthalmopathy associated with Graves disease may depend, in part, on the presence or absence of particular HLA antigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9860004     DOI: 10.1016/s0002-9394(98)00248-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

Review 1.  The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology.

Authors:  Eric M Jacobson; Amanda Huber; Yaron Tomer
Journal:  J Autoimmun       Date:  2008-01-04       Impact factor: 7.094

2.  Leptin receptor is a key gene involved in the immunopathogenesis of thyroid-associated ophthalmopathy.

Authors:  Ziyi Chen; Zhe Chen; Jingya Wang; Meng Zhang; Xiaofei Wang; Deji Cuomu; Bingyin Shi; Yue Wang
Journal:  J Cell Mol Med       Date:  2021-05-14       Impact factor: 5.310

3.  HLA alleles, especially amino-acid signatures of HLA-DPB1, might contribute to the molecular pathogenesis of early-onset autoimmune thyroid disease.

Authors:  Dong-Hwan Shin; In-Cheol Baek; Hyung Jae Kim; Eun-Jeong Choi; Moonbae Ahn; Min Ho Jung; Byung-Kyu Suh; Won Kyoung Cho; Tai-Gyu Kim
Journal:  PLoS One       Date:  2019-05-15       Impact factor: 3.240

4.  Association between HLA-B*46 allele and Graves disease in Asian populations: a meta-analysis.

Authors:  Yiping Li; Yufeng Yao; Man Yang; Li Shi; Xianli Li; Ying Yang; Ying Zhang; Chunjie Xiao
Journal:  Int J Med Sci       Date:  2013-01-03       Impact factor: 3.738

5.  Association of MICA Alleles with Autoimmune Thyroid Disease in Korean Children.

Authors:  Won Kyoung Cho; Min Ho Jung; So Hyun Park; In Cheol Baek; Hee-Baeg Choi; Tai-Gyu Kim; Byung-Kyu Suh
Journal:  Int J Endocrinol       Date:  2012-11-14       Impact factor: 3.257

6.  Human leucocyte antigen alleles confer susceptibility and progression to Graves' ophthalmopathy in a Southern Chinese population.

Authors:  Xiaosheng Huang; Guiqin Liu; Zhihui Deng; Jun Zhao; Shaoyi Mei; Jiamin Cai; Jing Rao; Minzhong Tang; Tianhui Zhu; Wenchiew Chen; Shiming Peng; Yan Wang; Ye Ye; Tong Zhang
Journal:  Br J Ophthalmol       Date:  2020-11-21       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.